Key Highlights

  • The pharmaceutical giant delivered Q1 adjusted earnings of $2.70 per share, surpassing analyst projections of $2.68, while revenue reached $24.1 billion against expectations of $23.6 billion.
  • The pharmaceutical segment generated $15.4 billion in revenue, marking an 11.2% annual increase, with Darzalex contributing $4.0B and Tremfya adding $1.6B.
  • Management elevated its full-year 2026 revenue projection to $100.8 billion and adjusted earnings forecast to $11.55 per share.
  • Analysts at Truist Securities project that Icotyde, J&J’s recently approved psoriasis oral medication, could generate approximately $10 billion in peak annual revenue.
  • Shares have advanced 15% during the first months of 2026, significantly outpacing the S&P 500’s 0.6-1% increase.

Johnson & Johnson unveiled its first-quarter 2026 financial performance on Tuesday morning, delivering results that exceeded Wall Street projections across key metrics.

Quarterly revenue reached $24.1 billion, representing a 10% year-over-year increase and surpassing the $23.6 billion consensus compiled by FactSet. Adjusted profit per share landed at $2.70, edging past the $2.68 analyst forecast.

Shares appreciated approximately 1.2% during premarket hours after the earnings release.


JNJ Stock Card
Johnson & Johnson, JNJ

The period marks another chapter in J&J’s strategic transformation. The healthcare conglomerate has redirected its focus toward pharmaceuticals and medical technology following the divestiture of its consumer health business — the Kenvue spinoff, currently subject to acquisition by Kimberly-Clark.

The pharmaceutical division delivered standout results, with revenue climbing 11.2% annually to $15.4 billion. This figure exceeded the FactSet consensus of $15.2 billion.

Darzalex, the company’s leading treatment for multiple myeloma, generated $4.0 billion during the quarter, advancing from $3.2 billion in the prior year. Analysts had anticipated $3.9 billion.

Tremfya, an IL-23 inhibitor addressing autoimmune disorders, recorded $1.6 billion in quarterly sales, jumping from $956 million in the comparable 2025 period and exceeding the $1.4 billion projection.

Autoimmune Treatment Advancement

Regulatory authorities cleared Tremfya’s subcutaneous formulation last September for ulcerative colitis and Crohn’s disease patients, establishing it as the first medication in its category available for home self-administration. This delivery method provides a competitive edge against AbbVie’s Skyrizi, which necessitates clinic-based infusions initially.

Last month, J&J secured FDA clearance for Icotyde, an innovative oral IL-23 inhibitor targeting plaque psoriasis, originating from a 2017 licensing agreement with Protagonist Therapeutics. Truist Securities analyst Srikripa Devarakonda forecasts Icotyde could achieve peak annual revenue approaching $10 billion. The company has yet to report sales data.

The medical technology segment contributed $8.6 billion in revenue, matching analyst expectations.

Net profit totaled $5.2 billion, falling short of the FactSet projection of $6.5 billion — representing the second straight quarter where bottom-line results trailed forecasts.

Updated Outlook and Ongoing Litigation

Management revised its full-year revenue expectation upward to $100.8 billion from the previous $100.5 billion target. Adjusted earnings per share guidance increased to $11.55 from $11.03. Wall Street had projected $11.54 per share on revenue of $100.6 billion.

The company continues to manage significant legal exposure. As of Q4 2025, J&J faced 74,360 pending lawsuits alleging its talcum powder products contained cancer-causing asbestos. A recent bankruptcy filing by subsidiary Red River Talc, intended to facilitate a comprehensive settlement, was rejected by a Texas court, permitting individual litigation to continue.

J&J maintains that its baby powder product, currently marketed under the Kenvue brand, meets safety standards and contains no asbestos.

Among 29 analyst firms monitored by FactSet, 17 assign JNJ a Buy rating or equivalent. Two firms recommend selling the stock.

Shares have climbed 15% year-to-date in 2026, substantially outperforming the S&P 500’s approximately 0.6% to 1% gain during the same timeframe.